FIELD: medicine.
SUBSTANCE: anti-Cd20 antibodies are administered in amount of 0.5-4.0 g. 16-60 weeks later administration is repeated. To 4 and more antibody effects are performed. Each effect comprises one or two dosages of antibody. Antibody can be introduced intravenously, subcutaneously or subtunically. The second medicine can be used therewith. A product containing the instructions and a container with 0.5-4.0 g of antibody. In addition, the product can contain the container with the second medicine and the application instructions.
EFFECT: invention allows for prolonged period before stated progression of disease, reduced recurrence rate.
38 cl, 6 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING VASCULITIS | 2005 |
|
RU2411956C2 |
| METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
| METHOD OF TREATING JOINT INJURIES | 2006 |
|
RU2457860C2 |
| METHOD FOR TREATING MULTIPLE SCLEROSIS | 2015 |
|
RU2757961C2 |
| USING ANTI-CD40-ANTIBODIES | 2008 |
|
RU2491095C2 |
| SCHEMES AND METHODS FOR TREATMENT OF MULTIPLE SCLEROSIS, USING OFATUMUMAB | 2017 |
|
RU2782069C2 |
| REGIMEN AND METHODS FOR MULTIPLE SCLEROSIS TREATMENT USING OFATUMUMAB | 2017 |
|
RU2749951C2 |
| COMBINED THERAPY BY AFUCOSYLATED ANTIBODY FOR CD20 WITH ANTIBODY FOR VEGF | 2011 |
|
RU2615459C2 |
| COMBINED THERAPY WITH AFUCOSYLATED CD20 ANTIBODY AND mTOR INHIBITOR | 2011 |
|
RU2585489C2 |
| DECREASING B-CELL COUNT WITH USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | 2006 |
|
RU2423381C2 |
